MCID: ACT095
MIFTS: 28

Acute Biphenotypic Leukemia

Categories: Cancer diseases

Aliases & Classifications for Acute Biphenotypic Leukemia

MalaCards integrated aliases for Acute Biphenotypic Leukemia:

Name: Acute Biphenotypic Leukemia 38 73

Classifications:



External Ids:

UMLS 73 C0023464

Summaries for Acute Biphenotypic Leukemia

MalaCards based summary : Acute Biphenotypic Leukemia is related to leukemia, acute myeloid and leukemia, acute lymphoblastic. An important gene associated with Acute Biphenotypic Leukemia is MPO (Myeloperoxidase), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and monocytes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute Biphenotypic Leukemia

Graphical network of the top 20 diseases related to Acute Biphenotypic Leukemia:



Diseases related to Acute Biphenotypic Leukemia

Symptoms & Phenotypes for Acute Biphenotypic Leukemia

GenomeRNAi Phenotypes related to Acute Biphenotypic Leukemia according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.6 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.6 DNTT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.6 DNTT
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.6 MPO
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.6 DNTT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.6 DNTT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.6 DNTT MPO
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.6 DNTT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.6 MPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.6 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.6 MPO
12 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.6 DNTT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.6 MPO
14 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.6 MPO
15 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.6 MPO
16 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.6 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.6 MPO
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.6 DNTT

Drugs & Therapeutics for Acute Biphenotypic Leukemia

Drugs for Acute Biphenotypic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 3 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
4
Methotrexate Approved Phase 3,Phase 1,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
5
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
6 tannic acid Approved Phase 3,Phase 2
7
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
8
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492
9
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
11 Cytochrome P-450 Enzyme Inhibitors Phase 3
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
14 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Infective Agents, Urinary Phase 3
17 Renal Agents Phase 3
18 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
19 Antirheumatic Agents Phase 3,Phase 1,Phase 2
20 Dermatologic Agents Phase 3,Phase 1,Phase 2
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
23 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
25 Vitamin B9 Phase 3,Phase 1,Phase 2
26 Folate Phase 3,Phase 1,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
29 Vitamin B Complex Phase 3,Phase 1,Phase 2
30 Calcineurin Inhibitors Phase 3,Phase 2
31 triamcinolone acetonide Phase 3
32 Triamcinolone diacetate Phase 3
33 Antitubercular Agents Phase 3,Phase 2
34 Triamcinolone hexacetonide Phase 3
35
Azacitidine Approved, Investigational Phase 2,Phase 1,Not Applicable 320-67-2 9444
36
Clofarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 123318-82-1 119182
37
Busulfan Approved, Investigational Phase 2,Phase 1,Not Applicable 55-98-1 2478
38
Fludarabine Approved Phase 1, Phase 2,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
39
Cytarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 147-94-4 6253
40
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 32326 21704
41
Nicotinamide Approved, Investigational Phase 1, Phase 2,Phase 2 98-92-0 936
42
Sorafenib Approved, Investigational Phase 1, Phase 2,Not Applicable 284461-73-0 216239 406563
43
Daunorubicin Approved Phase 2,Not Applicable 20830-81-3 30323
44
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 5754
45
Hydrocortisone acetate Approved, Vet_approved Phase 2,Phase 1 50-03-3
46
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Vincristine Approved, Investigational Phase 2,Phase 1 57-22-7, 2068-78-2 5978

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed NCT01371656 Phase 3 levofloxacin
2 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
3 Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT02399917 Phase 2 Azacitidine
4 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00990249 Phase 2 Busulfan;Clofarabine;Thymoglobulin
5 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
6 Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Recruiting NCT02135874 Phase 2 Clofarabine;Cytarabine;Dexamethasone;Idarubicin;Sorafenib Tosylate;Vincristine Sulfate
7 GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Recruiting NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
8 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Recruiting NCT03012672 Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
9 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT03399773 Phase 2 Cyclophosphamide;Fludarabine;Thiotepa
10 Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Recruiting NCT03267186 Phase 2 Ibrutinib
11 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
12 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02728050 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride;Sorafenib Tosylate
13 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting NCT03683433 Phase 2 Azacitidine;Enasidenib Mesylate
14 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02397720 Phase 2 Azacitidine
15 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
16 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting NCT00796068 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Treosulfan
17 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
18 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
19 Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting NCT02115295 Phase 2 Cladribine;Cytarabine;Idarubicin;Midostaurin
20 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Active, not recruiting NCT01690520 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
21 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Active, not recruiting NCT01858740 Phase 2 Fludarabine Phosphate;Methotrexate;Tacrolimus;Thiotepa
22 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Active, not recruiting NCT02044796 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
23 Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Active, not recruiting NCT02921061 Phase 1, Phase 2 Cladribine;Cytarabine;Decitabine;Mitoxantrone Hydrochloride
24 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Active, not recruiting NCT00723099 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
25 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Not yet recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
26 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
27 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Suspended NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
28 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2 Bortezomib;Vorinostat;Mitoxantrone;Cytarabine;Methotrexate;Hydrocortisone;Peg-L-Asparaginase;Erwinia L-Asparaginase;Dexamethasone;Mercaptopurine;Doxorubicin
29 Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Terminated NCT03195010 Phase 2
30 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Withdrawn NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
31 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1 Selinexor;Fludarabine;Cytarabine;methotrexate/hydrocortisone/cytarabine
32 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT02270788 Phase 1 Crenolanib;Sorafenib;methotrexate, hydrocortisone and cytarabine with leucovorin
33 Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Completed NCT01132573 Phase 1 entinostat;clofarabine
34 POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Completed NCT01319864 Phase 1 Plerixafor Dose Escalation
35 AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Completed NCT01431664 Phase 1 multikinase inhibitor AT9283
36 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
37 Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage Recruiting NCT03194932 Phase 1 Venetoclax;Cytarabine;Idarubicin;Intrathecal Triple Therapy
38 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
39 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT01925131 Phase 1 cyclophosphamide;vincristine sulfate;prednisone
40 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
41 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting NCT03326921 Phase 1 Fludarabine Phosphate
42 Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders Recruiting NCT03198234 Phase 1
43 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting NCT03807063 Phase 1 Rimiducid
44 Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Terminated NCT01887587 Phase 1 MLN9708;Vincristine;Doxorubicin;Dexamethasone
45 Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated NCT01701323 Phase 1 Cytarabine;Filgrastim;Fludarabine Phosphate
46 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1 dexrazoxane hydrochloride;doxorubicin hydrochloride;obatoclax mesylate;liposomal vincristine sulfate
47 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Withdrawn NCT02578511 Phase 1 Ixazomib
48 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed NCT01804101 Not Applicable Liposomal Cytarabine-Daunorubicin CPX-351
49 Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Completed NCT00013533 Early Phase 1
50 Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) Recruiting NCT03496402 Not Applicable

Search NIH Clinical Center for Acute Biphenotypic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Biphenotypic Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Biphenotypic Leukemia

Anatomical Context for Acute Biphenotypic Leukemia

MalaCards organs/tissues related to Acute Biphenotypic Leukemia:

41
Myeloid, Bone, Monocytes, T Cells, Bone Marrow

Publications for Acute Biphenotypic Leukemia

Articles related to Acute Biphenotypic Leukemia:

(show all 25)
# Title Authors Year
1
Lateral pharyngeal wall myeloid sarcoma as a relapse of acute biphenotypic leukemia: a case report and review of the literature. ( 24377982 )
2013
2
Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis. ( 24086946 )
2013
3
Activation of a novel palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia. ( 21151021 )
2011
4
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy. ( 19752004 )
2009
5
Cryptic insertion into 11q23 of MLLT10 not involved in t(1;15;11;10)(p36;q11;q23;q24) in infant acute biphenotypic leukemia. ( 19380030 )
2009
6
Successful voriconazole treatment of invasive pulmonary aspergillosis in a patient with acute biphenotypic leukemia. ( 19727206 )
2009
7
Nelarabine activity in acute biphenotypic leukemia. ( 17512588 )
2007
8
Bridging necrosis and reticulin bridging fibrosis induced by intrahepatic involvement of acute biphenotypic leukemia. ( 17207092 )
2006
9
Arthritis preceding acute biphenotypic leukemia. ( 16220224 )
2006
10
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( 16823822 )
2006
11
Acute biphenotypic leukemia and an acquired X chromosome. ( 15676158 )
2005
12
Trisomy 4 as the sole karyotypic abnormality in a case of acute biphenotypic leukemia with T-lineage markers in minimally differentiated acute myelocytic leukemia. ( 15041226 )
2004
13
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). ( 15060424 )
2004
14
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. ( 12953816 )
2003
15
Acute biphenotypic leukemia in the adults. ( 12408768 )
2002
16
Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia. ( 9790503 )
1998
17
Definition of acute biphenotypic leukemia. ( 9107085 )
1997
18
Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (M0). ( 7697636 )
1995
19
An adult case of acute biphenotypic leukemia with characteristic mixed morphology. ( 8232165 )
1993
20
Chromosome 21 rearrangement in acute biphenotypic leukemia. ( 1360869 )
1992
21
Surface marker analysis and karyotype distinguish acute biphenotypic leukemia from acute myelogenous leukemia expressing terminal deoxynucleotidyl transferase. ( 1913454 )
1991
22
Translocation (14;19) in acute biphenotypic leukemia. ( 1903671 )
1991
23
Trisomy 4 in a case of acute biphenotypic leukemia. ( 2357699 )
1990
24
Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin. ( 2838522 )
1988
25
Inv(16) occurring in a case of acute biphenotypic leukemia lacking monocytic markers: multiple but short remissions. ( 3470123 )
1987

Variations for Acute Biphenotypic Leukemia

Expression for Acute Biphenotypic Leukemia

Search GEO for disease gene expression data for Acute Biphenotypic Leukemia.

Pathways for Acute Biphenotypic Leukemia

Pathways related to Acute Biphenotypic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 KMT2A MPO

GO Terms for Acute Biphenotypic Leukemia

Molecular functions related to Acute Biphenotypic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 8.92 DNTT KMT2A MLLT10 MPO

Sources for Acute Biphenotypic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....